Uptake of hepatitis C virus treatment in HIV/hepatitis C virus-coinfected patients across Europe in the era of direct-acting antivirals
To investigate the uptake of hepatitis C virus (HCV) therapy among HIV/HCV-coinfected patients in the pan-European EuroSIDA study between 2011 and 2016. All HCV-RNA+ patients were included. Baseline was defined as latest of anti-HCV+, January 2011 or enrolment in EuroSIDA. The incidence of starting...
Uložené v:
| Vydané v: | AIDS (London) Ročník 32; číslo 14; s. 1995 |
|---|---|
| Hlavní autori: | , , , , , , , , , , , , , , , , , , , , , |
| Médium: | Journal Article |
| Jazyk: | English |
| Vydavateľské údaje: |
England
10.09.2018
|
| ISSN: | 1473-5571, 1473-5571 |
| On-line prístup: | Zistit podrobnosti o prístupe |
| Tagy: |
Pridať tag
Žiadne tagy, Buďte prvý, kto otaguje tento záznam!
|
| Abstract | To investigate the uptake of hepatitis C virus (HCV) therapy among HIV/HCV-coinfected patients in the pan-European EuroSIDA study between 2011 and 2016.
All HCV-RNA+ patients were included. Baseline was defined as latest of anti-HCV+, January 2011 or enrolment in EuroSIDA. The incidence of starting first interferon-free direct-acting antiviral (DAA) therapy was calculated. Factors associated with starting interferon-free DAA were determined by Poisson regression.
Among 4308 HCV-RNA+ patients (1255, 970, 663, 633, 787 from South, West, North, Central East and East Europe, respectively) with 11 863 person-years of follow-up, 1113 (25.8%) started any HCV therapy. Among patients with at least F3 fibrosis, more than 50% in all regions remained untreated. The incidence (per 1000 person-years of follow-up, 95% confidence interval) of starting DAA increased from 7.8 (5.9-9.8) in 2014 to 135.2 (122.0-148.5) in 2015 and 128.9 (113.5-144.3) in 2016. The increase was highest in North and West and intermediate in South, but remained modest in Central East and Eastern Europe. After adjustment, women, individuals from Central East or East, genotype 3, antiretroviral therapy naïve and those with detectable HIV-RNA were less likely to start DAA. Older persons, those with HCV-RNA more than 500 000 IU/ml and those with more advanced liver fibrosis were more likely to start DAA.
Uptake of DAA therapy among HIV/HCV-coinfected patients increased considerably in Western Europe between 2014 and 2016, but was modest in Central East and East. In all regions more than 50% with at least F3 fibrosis remained untreated. Women were less likely to start DAA. |
|---|---|
| AbstractList | To investigate the uptake of hepatitis C virus (HCV) therapy among HIV/HCV-coinfected patients in the pan-European EuroSIDA study between 2011 and 2016.BACKGROUND AND AIMSTo investigate the uptake of hepatitis C virus (HCV) therapy among HIV/HCV-coinfected patients in the pan-European EuroSIDA study between 2011 and 2016.All HCV-RNA+ patients were included. Baseline was defined as latest of anti-HCV+, January 2011 or enrolment in EuroSIDA. The incidence of starting first interferon-free direct-acting antiviral (DAA) therapy was calculated. Factors associated with starting interferon-free DAA were determined by Poisson regression.METHODSAll HCV-RNA+ patients were included. Baseline was defined as latest of anti-HCV+, January 2011 or enrolment in EuroSIDA. The incidence of starting first interferon-free direct-acting antiviral (DAA) therapy was calculated. Factors associated with starting interferon-free DAA were determined by Poisson regression.Among 4308 HCV-RNA+ patients (1255, 970, 663, 633, 787 from South, West, North, Central East and East Europe, respectively) with 11 863 person-years of follow-up, 1113 (25.8%) started any HCV therapy. Among patients with at least F3 fibrosis, more than 50% in all regions remained untreated. The incidence (per 1000 person-years of follow-up, 95% confidence interval) of starting DAA increased from 7.8 (5.9-9.8) in 2014 to 135.2 (122.0-148.5) in 2015 and 128.9 (113.5-144.3) in 2016. The increase was highest in North and West and intermediate in South, but remained modest in Central East and Eastern Europe. After adjustment, women, individuals from Central East or East, genotype 3, antiretroviral therapy naïve and those with detectable HIV-RNA were less likely to start DAA. Older persons, those with HCV-RNA more than 500 000 IU/ml and those with more advanced liver fibrosis were more likely to start DAA.RESULTSAmong 4308 HCV-RNA+ patients (1255, 970, 663, 633, 787 from South, West, North, Central East and East Europe, respectively) with 11 863 person-years of follow-up, 1113 (25.8%) started any HCV therapy. Among patients with at least F3 fibrosis, more than 50% in all regions remained untreated. The incidence (per 1000 person-years of follow-up, 95% confidence interval) of starting DAA increased from 7.8 (5.9-9.8) in 2014 to 135.2 (122.0-148.5) in 2015 and 128.9 (113.5-144.3) in 2016. The increase was highest in North and West and intermediate in South, but remained modest in Central East and Eastern Europe. After adjustment, women, individuals from Central East or East, genotype 3, antiretroviral therapy naïve and those with detectable HIV-RNA were less likely to start DAA. Older persons, those with HCV-RNA more than 500 000 IU/ml and those with more advanced liver fibrosis were more likely to start DAA.Uptake of DAA therapy among HIV/HCV-coinfected patients increased considerably in Western Europe between 2014 and 2016, but was modest in Central East and East. In all regions more than 50% with at least F3 fibrosis remained untreated. Women were less likely to start DAA.CONCLUSIONUptake of DAA therapy among HIV/HCV-coinfected patients increased considerably in Western Europe between 2014 and 2016, but was modest in Central East and East. In all regions more than 50% with at least F3 fibrosis remained untreated. Women were less likely to start DAA. To investigate the uptake of hepatitis C virus (HCV) therapy among HIV/HCV-coinfected patients in the pan-European EuroSIDA study between 2011 and 2016. All HCV-RNA+ patients were included. Baseline was defined as latest of anti-HCV+, January 2011 or enrolment in EuroSIDA. The incidence of starting first interferon-free direct-acting antiviral (DAA) therapy was calculated. Factors associated with starting interferon-free DAA were determined by Poisson regression. Among 4308 HCV-RNA+ patients (1255, 970, 663, 633, 787 from South, West, North, Central East and East Europe, respectively) with 11 863 person-years of follow-up, 1113 (25.8%) started any HCV therapy. Among patients with at least F3 fibrosis, more than 50% in all regions remained untreated. The incidence (per 1000 person-years of follow-up, 95% confidence interval) of starting DAA increased from 7.8 (5.9-9.8) in 2014 to 135.2 (122.0-148.5) in 2015 and 128.9 (113.5-144.3) in 2016. The increase was highest in North and West and intermediate in South, but remained modest in Central East and Eastern Europe. After adjustment, women, individuals from Central East or East, genotype 3, antiretroviral therapy naïve and those with detectable HIV-RNA were less likely to start DAA. Older persons, those with HCV-RNA more than 500 000 IU/ml and those with more advanced liver fibrosis were more likely to start DAA. Uptake of DAA therapy among HIV/HCV-coinfected patients increased considerably in Western Europe between 2014 and 2016, but was modest in Central East and East. In all regions more than 50% with at least F3 fibrosis remained untreated. Women were less likely to start DAA. |
| Author | Del Campo, Santos Peters, Lars Mocroft, Amanda Khromova, Irina Trofimova, Tatyana Matulionyte, Raimonda Rauch, Andri Mitsura, Viktar Rockstroh, Jürgen Leen, Clifford Domingo, Pere Lundgren, Jens Laut, Kamilla Falconer, Karolin Zangerle, Robert Lacombe, Karine Paduta, Dzmitry Gatell, Jose Resnati, Chiara Benfield, Thomas Zilmer, Kai Chkhartishvili, Nikoloz |
| Author_xml | – sequence: 1 givenname: Lars surname: Peters fullname: Peters, Lars organization: CHIP, Department of Infectious Diseases, Rigshospitalet, University of Copenhagen, Copenhagen, Denmark – sequence: 2 givenname: Kamilla surname: Laut fullname: Laut, Kamilla organization: CHIP, Department of Infectious Diseases, Rigshospitalet, University of Copenhagen, Copenhagen, Denmark – sequence: 3 givenname: Chiara surname: Resnati fullname: Resnati, Chiara organization: Department of Infectious Diseases, Luigi Sacco University Hospital, Milan, Italy – sequence: 4 givenname: Santos surname: Del Campo fullname: Del Campo, Santos organization: Hospital Universitario Ramón y Cajal, Departamento de Gastroenterología, Madrid, Spain – sequence: 5 givenname: Clifford surname: Leen fullname: Leen, Clifford organization: Regional Infectious Diseases Unit, Western General Hospital, Edinburgh, UK – sequence: 6 givenname: Karolin surname: Falconer fullname: Falconer, Karolin organization: Infectious Diseases Department, Karolinska University Hospital, Stockholm, Sweden – sequence: 7 givenname: Tatyana surname: Trofimova fullname: Trofimova, Tatyana organization: Novgorod Centre for AIDS Prevention and Control, Velikij, Novgorod, Russia – sequence: 8 givenname: Dzmitry surname: Paduta fullname: Paduta, Dzmitry organization: Epidemiology and Healthcare, Gomel Regional Centre for Hygiene, Gomel, Belarus – sequence: 9 givenname: Jose surname: Gatell fullname: Gatell, Jose organization: Hospital Clinic Universitari de Barcelona, Barcelona, Spain – sequence: 10 givenname: Andri surname: Rauch fullname: Rauch, Andri organization: Department of Infectious Diseases, Inselspital, Bern University Hospital, University of Bern, Bern, Switzerland – sequence: 11 givenname: Karine surname: Lacombe fullname: Lacombe, Karine organization: Hospital Saint-Antoine, Paris, France – sequence: 12 givenname: Pere surname: Domingo fullname: Domingo, Pere organization: Hospital de la Santa Creu i Sant Pau, Barcelona, Spain – sequence: 13 givenname: Nikoloz surname: Chkhartishvili fullname: Chkhartishvili, Nikoloz organization: Infectious Diseases, AIDS and Clinical Immunology Research Center, Tbilisi, Georgia – sequence: 14 givenname: Robert surname: Zangerle fullname: Zangerle, Robert organization: Medical University of Innsbruck, Department of Dermatology, Venereology and Allergology, Innsbruck, Austria – sequence: 15 givenname: Raimonda surname: Matulionyte fullname: Matulionyte, Raimonda organization: Centre of Infectious Diseases, Vilnius University Hospital Santaros Klinikos, Vilnius, Lithuania – sequence: 16 givenname: Viktar surname: Mitsura fullname: Mitsura, Viktar organization: Infectious Diseases Department, Gomel State Medical University, Gomel, Belarus – sequence: 17 givenname: Thomas surname: Benfield fullname: Benfield, Thomas organization: Department of Infectious Diseases, Hvidovre Hospital, Copenhagen, Denmark – sequence: 18 givenname: Kai surname: Zilmer fullname: Zilmer, Kai organization: Centre of Infectious Diseases, West-Tallinn Central Hospital, Tallinn, Estonia – sequence: 19 givenname: Irina surname: Khromova fullname: Khromova, Irina organization: Centre for HIV/AIDS & Infectious Diseases, Kaliningrad, Russia – sequence: 20 givenname: Jens surname: Lundgren fullname: Lundgren, Jens organization: CHIP, Department of Infectious Diseases, Rigshospitalet, University of Copenhagen, Copenhagen, Denmark – sequence: 21 givenname: Jürgen surname: Rockstroh fullname: Rockstroh, Jürgen organization: University of Bonn, Department of Medicine I, Bonn, Germany – sequence: 22 givenname: Amanda surname: Mocroft fullname: Mocroft, Amanda organization: Centre for Clinical Research, Epidemiology, Modelling and Evaluation (CREME), Institute for Global Health, University College London, London, UK |
| BackLink | https://www.ncbi.nlm.nih.gov/pubmed/29912062$$D View this record in MEDLINE/PubMed |
| BookMark | eNplkF9LwzAUxYNM3B_9BiJ59KVbkq5J8zjmdIOBCM7Xkqa3LrqmNUkFP4Ff2xYnDLwv58L53XPgjtHA1hYQuqZkSokUs6fF3ZScDJUsPUMjOhdxlCSCDk72IRp7_9ZBCUnTCzRkUlJGOBuh710T1DvgusR7aFQwwXi8xJ_GtR4HBypUYAM2Fq83L7N_SKRrY0vQAQrcWx3rsdKu9h6vWlc30J-GPWBwqi8pjOvoSOlg7CtWNpguRx38JTovO4Gro07Q7n71vFxH28eHzXKxjfRcEBIBz0tFBYllrMpiDhwE0ZqnMS2kZlyUTOQ5y4UA2fk0FxISCVIyCYSIkrIJuv3NbVz90YIPWWW8hsNBWahbnzGScMFpmvTozRFt8wqKrHGmUu4r-3se-wGr9HWd |
| CitedBy_id | crossref_primary_10_1093_cid_ciac231 crossref_primary_10_21101_cejph_a5486 crossref_primary_10_1111_liv_15754 crossref_primary_10_1093_infdis_jiz069 crossref_primary_10_1097_QAD_0000000000003159 crossref_primary_10_3390_vaccines11050980 crossref_primary_10_1111_hiv_12711 crossref_primary_10_1111_hiv_12810 crossref_primary_10_1097_QAD_0000000000003112 crossref_primary_10_1177_0956462419866055 crossref_primary_10_1097_QAD_0000000000003670 crossref_primary_10_1097_QAD_0000000000004161 crossref_primary_10_1002_jia2_26166 crossref_primary_10_1007_s10461_021_03214_y crossref_primary_10_1111_hiv_13163 crossref_primary_10_1136_bmjopen_2018_027411 crossref_primary_10_3390_v16060885 crossref_primary_10_1097_QAD_0000000000003406 crossref_primary_10_3390_ijerph192215237 crossref_primary_10_1093_ofid_ofac508 crossref_primary_10_3748_wjg_v26_i38_5874 crossref_primary_10_1093_ofid_ofaa470 crossref_primary_10_1097_QAD_0000000000002570 crossref_primary_10_1111_hiv_13357 crossref_primary_10_1093_cid_ciaa1940 crossref_primary_10_1186_s12879_021_06521_w |
| ContentType | Journal Article |
| CorporateAuthor | EuroSIDA Study Group |
| CorporateAuthor_xml | – name: EuroSIDA Study Group |
| DBID | NPM 7X8 |
| DOI | 10.1097/QAD.0000000000001928 |
| DatabaseName | PubMed MEDLINE - Academic |
| DatabaseTitle | PubMed MEDLINE - Academic |
| DatabaseTitleList | MEDLINE - Academic PubMed |
| Database_xml | – sequence: 1 dbid: NPM name: PubMed url: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: 7X8 name: MEDLINE - Academic url: https://search.proquest.com/medline sourceTypes: Aggregation Database |
| DeliveryMethod | no_fulltext_linktorsrc |
| Discipline | Medicine |
| EISSN | 1473-5571 |
| ExternalDocumentID | 29912062 |
| Genre | Research Support, Non-U.S. Gov't Journal Article |
| GroupedDBID | --- .XZ .Z2 01R 0R~ 1J1 23M 2WC 354 40H 4Q1 4Q2 4Q3 5GY 5RE 5VS 71W 77Y 7O~ 85S 8L- AAAAV AAAXR AAGIX AAHPQ AAIQE AAJCS AAMOA AAMTA AAQKA AARTV AASCR AASOK AASXQ AAUEB AAXQO ABASU ABBUW ABDIG ABIVO ABJNI ABVCZ ABXVJ ABXYN ABZAD ABZZY ACCJW ACDDN ACDOF ACEWG ACGFS ACIJW ACILI ACLDA ACOAL ACWDW ACWRI ACXJB ACXNZ ACZKN ADBBV ADGGA ADHPY AE3 AE6 AEBDS AEETU AENEX AFBFQ AFDTB AFEXH AFMBP AFNMH AFSOK AFUWQ AGINI AHOMT AHQNM AHQVU AHVBC AIJEX AINUH AJCLO AJIOK AJNWD AJZMW AKCTQ AKULP ALKUP ALMA_UNASSIGNED_HOLDINGS ALMTX AMJPA AMKUR AMNEI AOHHW AOQMC BAWUL BOYCO BQLVK BYPQX C45 CS3 DIK DIWNM E.X E3Z EBS EEVPB EJD ERAAH EX3 F2K F2L F2M F2N F5P FCALG FL- GNXGY GQDEL H0~ HLJTE HZ~ IKREB IKYAY IN~ IPNFZ JK3 JK8 K8S KD2 KMI KQ8 L-C L7B N9A NPM N~7 N~B O9- OAG OAH OBH ODMTH OHH OHYEH OK1 OL1 OLB OLG OLH OLU OLV OLY OLZ OPUJH OPX OVD OVDNE OVIDH OVLEI OVOZU OWU OWV OWW OWX OWY OWZ OXXIT P2P RIG RLZ S4R S4S SJN TEORI TR2 TSPGW V2I VVN W3M WOQ WOW X3V X3W XXN XYM YFH 7X8 ABPXF ACBKD ADKSD ADSXY |
| ID | FETCH-LOGICAL-c4700-e6bfa170393afd4e6e70cc6831d9c267f27bb2b77e9afd1b79e59e9929e007f12 |
| IEDL.DBID | 7X8 |
| ISICitedReferencesCount | 27 |
| ISICitedReferencesURI | http://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=Summon&SrcAuth=ProQuest&DestLinkType=CitingArticles&DestApp=WOS_CPL&KeyUT=00002030-201809100-00010&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D |
| ISSN | 1473-5571 |
| IngestDate | Sun Nov 09 11:03:54 EST 2025 Thu Apr 03 06:53:43 EDT 2025 |
| IsDoiOpenAccess | false |
| IsOpenAccess | true |
| IsPeerReviewed | true |
| IsScholarly | true |
| Issue | 14 |
| Language | English |
| LinkModel | DirectLink |
| MergedId | FETCHMERGED-LOGICAL-c4700-e6bfa170393afd4e6e70cc6831d9c267f27bb2b77e9afd1b79e59e9929e007f12 |
| Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23 ObjectType-Undefined-3 |
| OpenAccessLink | http://www.who.int/medicines/publications/essentialmedicines/20th_EML2017_FINAL_amendedAug2017.pdf?ua=1 |
| PMID | 29912062 |
| PQID | 2056761851 |
| PQPubID | 23479 |
| ParticipantIDs | proquest_miscellaneous_2056761851 pubmed_primary_29912062 |
| PublicationCentury | 2000 |
| PublicationDate | 2018-September-10 |
| PublicationDateYYYYMMDD | 2018-09-10 |
| PublicationDate_xml | – month: 09 year: 2018 text: 2018-September-10 day: 10 |
| PublicationDecade | 2010 |
| PublicationPlace | England |
| PublicationPlace_xml | – name: England |
| PublicationTitle | AIDS (London) |
| PublicationTitleAlternate | AIDS |
| PublicationYear | 2018 |
| SSID | ssj0005088 |
| Score | 2.405186 |
| Snippet | To investigate the uptake of hepatitis C virus (HCV) therapy among HIV/HCV-coinfected patients in the pan-European EuroSIDA study between 2011 and 2016.
All... To investigate the uptake of hepatitis C virus (HCV) therapy among HIV/HCV-coinfected patients in the pan-European EuroSIDA study between 2011 and... |
| SourceID | proquest pubmed |
| SourceType | Aggregation Database Index Database |
| StartPage | 1995 |
| Title | Uptake of hepatitis C virus treatment in HIV/hepatitis C virus-coinfected patients across Europe in the era of direct-acting antivirals |
| URI | https://www.ncbi.nlm.nih.gov/pubmed/29912062 https://www.proquest.com/docview/2056761851 |
| Volume | 32 |
| WOSCitedRecordID | wos00002030-201809100-00010&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D |
| hasFullText | |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| link | http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwpV1LS8NAEF7Uinjx_X6wgteleTWbPYlUix5aKljprexjVoOS1Kb1L_i3nU1SexBBMIdckiXZ3WHnm5lvZgi59GQkQpXETGiwLILYMhkYV7ZSIVwIIwBQZbMJ3uslw6Ho1w63oqZVzs_E8qA2uXY-cjTSWzGa3AgQrsbvzHWNctHVuoXGMmmECGUcpYsPF9XCHfgos4t4yFot7s9T5wRvPlzfVKUL6wuBTvI7yCyVTWfzv7-5RTZqmEmvK7nYJkuQ7ZC1bh1I3yWfg_FUvgLNLX0BR6qepgVt0490MivoN_mcphm9u39q_niF6bxicYGhdWXWgspS49LKv--GIrakMJHuI5XmZC6LInumuJupIxe_FXtk0Ll9bN-xuicD0xH3PAaxstLnLqNXWoN7C9zTOk5C3wgdxNwGXKlAcQ4Cn_uKC2gJEAjCANGI9YN9spLlGRwSKsG3JhHAubMBPZMoE4dGSxdLhYgnR-RivsQjlHkXyJAZ5LNitFjkI3JQ7dNoXBXnGKF69QMvDo7_MPqErCP-KekfvndKGhbnDWdkVX_gik7OS2HCe6_f_QKRnNUz |
| linkProvider | ProQuest |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Uptake+of+hepatitis+C+virus+treatment+in+HIV%2Fhepatitis+C+virus-coinfected+patients+across+Europe+in+the+era+of+direct-acting+antivirals&rft.jtitle=AIDS+%28London%29&rft.au=Peters%2C+Lars&rft.au=Laut%2C+Kamilla&rft.au=Resnati%2C+Chiara&rft.au=Del+Campo%2C+Santos&rft.date=2018-09-10&rft.eissn=1473-5571&rft.volume=32&rft.issue=14&rft.spage=1995&rft_id=info:doi/10.1097%2FQAD.0000000000001928&rft_id=info%3Apmid%2F29912062&rft_id=info%3Apmid%2F29912062&rft.externalDocID=29912062 |
| thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1473-5571&client=summon |
| thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1473-5571&client=summon |
| thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1473-5571&client=summon |